PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3395251

The Inhalation Hazard Test; principle and method.

H J Klimisch
View original source ↗Export metadata ↓

Abstract

The Inhalation Hazard Test (IHT) measures the hazard rather than the toxicity of volatile substances. Generation methods for saturated vapor atmospheres and exposure systems are described. The determination of the nominal concentration gives in most cases sufficient information on the concentration in the inhalation atmosphere. The temperature at which the saturation occurs and the exposure time are parameters which influence the test results. The determination of the LT0 (the exposure time at which no animals die) is used to compare substances with different inhalation hazards. A classification system is proposed to differentiate the toxic hazard of volatile substances. The IHT is an appropriate method to characterize the acute inhalation hazard of volatile substances. It requires fewer animals and is less elaborate than the LC50.

Explore related subjects

Administration, InhalationAerosolsAnimalsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H J Klimisch. 1988. The Inhalation Hazard Test; principle and method.. https://doi.org/10.1007/bf00334623

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2008

Concurrent carbogen and radiation therapy in children with high-risk brainstem gliomas.

In an attempt to improve local control, we assessed the feasibility of the addition of 4 min of carbogen inhalation (as a radiosensitizer) to daily fractionated radiotherapy in pediatric patients with high grade and/or diffuse brainstem gliomas. Ten patients inhaled carbogen for >90% of the radiation treatments. Median survival time from start of therapy was 0.80 years. Carbogen inhalation did not appear to improve the dismal prognosis.

Administration, Inhalation↗
PubMed2007

2. Advances in pharmacotherapy for COPD.

Chronic obstructive pulmonary disease (COPD) is the most common chronic lung disease in the world. In 1999, COPD ranked sixth among the most common causes of death and twelfth as a worldwide burden of disease. It has been estimated that by the year 2020 COPD will be the third leading cause of death and fifth as a worldwide burden of disease. Thus, COPD is a major medical problem and there is evidence that it is increasing throughout the world. Despite recognition of COPD as an important international health problem, COPD has been neglected among common diseases, with little investment in research on its underlying cellular and molecular mechanisms. Recently, global and Japanese guidelines for COPD have been published. These guidelines seem to be useful to improve the underdiagnosis and undertreatment of COPD. In this review, I describe briefly the current recommendation for pharmacological therapy of stable COPD according to the global and Japanese guidelines for COPD.

Administration, Inhalation↗